Pathogen Acquisition in Patients with Cystic Fibrosis Receiving Ivacaftor or Lumacaftor/Ivacaftor

BACKGROUND: The CFTR modulators ivacaftor and lumacaftor/ivacaftor improve the status of existing infections in patients with cystic fibrosis (CF). It is unknown how well these drugs protect patients against incident infections. We hypothesized that CFTR modulator treatment would decrease new infect...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Pediatr Pulmonol
Main Authors: Singh, Sachinkumar B., McLearn-Montz, Amanda J., Milavetz, Francesca, Gates, Levi K., Fox, Christopher, Murry, Logan T., Sabus, Ashley, Porterfield, Harry S., Fischer, Anthony J.
Format: Artigo
Sprog:Inglês
Udgivet: 2019
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6641998/
https://ncbi.nlm.nih.gov/pubmed/31012285
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ppul.24341
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker